Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Apatinib with Chemotherapy in 1L ESCC
NCT03603756Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jul 2018
- Primary completion
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03603756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603756.